Fundz

Frits Van Alphen, MD Appointed as Chief Development Officer (CDO) at Memo Therapeutics AG (MTx)

RECENTLY ACQUIREDNov 05, 2024

Position

Chief Development Officer

Company

Memo Therapeutics AG

Frits van Alphen
SchlierenBiotechnologyHealth CareScience And Engineering

Description

Frits van Alphen, MD has been appointed as chief development officer (CDO) at Memo Therapeutics AG (MTx), succeeding Dr. Gerald P Parzmair. Frits brings 30 years of international experience in clinical development and medical affairs.

Quick answer

Frits Van Alphen, MD Appointed as Chief Development Officer (CDO) at Memo Therapeutics AG (MTx) (November 5, 2024). Memo Therapeutics AG is based in Schlieren, Zurich, Switzerland.

Who is the new Chief Development Officer at Memo Therapeutics AG?
Memo Therapeutics AG named Frits van Alphen Chief Development Officer, announced November 5, 2024.
What did Memo Therapeutics AG announce on November 5, 2024?
Frits van Alphen, MD has been appointed as chief development officer (CDO) at Memo Therapeutics AG (MTx), succeeding Dr. Gerald P Parzmair. Frits brings 30 years of international experience in clinical development and medical affairs.
What does Memo Therapeutics AG do?
Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis.
Where is Memo Therapeutics AG based?
Memo Therapeutics AG is based in Schlieren, Zurich, Switzerland.
Which similar companies made leadership changes around the same time?
Koneksa Health (November 11, 2024), Kyverna Therapeutics (October 21, 2024), Abalos (October 9, 2024) and Wheeler Bio (October 9, 2024) also announced leadership changes within 45 days of Memo Therapeutics AG.

Source: Fundz verified event record.

Other recent leadership changes in Science And Engineering and Biotechnology

Executive moves at companies in the same sectors within 45 days, from Fundz verified event records.

Who to call at Memo Therapeutics AG, and when

A new leader at Memo Therapeutics AG brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day Memo Therapeutics AG raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Memo Therapeutics AG, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Memo Therapeutics AG. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Memo Therapeutics AG

Location

Schlieren, Zurich, Switzerland

About

Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis. The company’s antibody discovery platform uses robust, simple, and fast microfluidic single-cell molecular cloning and screening technologies to enable antibody repertoire mining and antibody discovery at unprecedented speed, efficiency, and sensitivity. The platform captures and preserves entire B-cell repertoires from any donor species and any B-cell type in recombinant form for display using mammalian cells. The antibody repertoires are subsequently screened in single-cell format using microfluidic screening technology that can assess millions of candidate antibodies directly in functional assays, resulting in recombinant clonal cell lines expressing monoclonal antibodies (mAbs) with the desired functional properties. Exploiting the power of its microfluidic single-cell molecular cloning and screening technologies, Memo Therapeutics AG engages in antibody discovery across species and indications for proprietary and partnered projects. The company’s current pipeline features programs in infectious diseases and immuno-oncology. Memo Therapeutics AG is a private company located in Bio-Technopark Zurich, Switzerland.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Memo Therapeutics AG changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Juergen
Likely contact at this company
••••••••@••••••••

See Juergen's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for Memo Therapeutics AG's next move

Learn about Strategic plan

Memo Therapeutics AG changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.